In Germany, carriers of pathogenic variants in ATM, BRCA1, BRCA2, BARD1, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53 are eligible for the intensified breast cancer surveillance (IBCS) program, which includes annual breast MRI as a core component [1]. Here, CHEK2 is linked to breast cancer.